Aytu BioPharma (AYTU) Q1 2027 earnings review
Aytu's depression drug grows fast, and Rosemont buys the business
Aytu BioPharma, a maker of prescription drugs for depression and attention disorders, agreed to sell itself for cash as its newest medicine grows and its older franchise shrinks. First-quarter sales rose 7% from a year ago to $15 million because chief executive Josh Disbrow pushed EXXUA, its new depression pill, up 25% from last quarter to $4.9 million. That growth was needed to cover a sharp drop in older attention-deficit medicines, while launch and legal bills pushed the company to a $3.9 million loss.
| Net revenue | $14.8M +6.9% from a year ago |
|---|---|
| EXXUA depression drug sales | $4.9M +24.5% from last quarter |
| ADHD portfolio sales | $7.7M -41.2% from a year ago |
| Buyout agreement | $2.70/share ~$56M cash deal with Rosemont |
βοΈ Verdict: βͺ Neutral
The standalone story is unchanged, though the $56 million cash buyout agreement with Rosemont Pharmaceuticals now caps the outcome for shareholders if it closes by December. EXXUA prescriptions re-accelerated to 4,400 in the quarter after a late-summer pause, proving doctors are adopting the drug. The bad news: attention-deficit drug sales dropped 41% from a year ago, eating up all of EXXUA's gains and driving operating profit before one-offs back into a $2.6 million loss.
The question now is whether the Rosemont tender offer closes smoothly by year-end, or if Aytu must fund its launch losses alone. If the deal closes, shareholders collect $2.70 per share in cash; if it fails, the company faces an expensive launch with a shrinking legacy business. The tender offer filings and year-end closing vote will settle it.
π Bull Case
EXXUA Prescriptions Re-accelerated in September
"Our first quarter performance was driven by growth in EXXUA, with net revenue increasing to $4.9 million and total prescriptions growing to 4,400 for the quarter," chief executive Josh Disbrow said. EXXUA is Aytu's new daily pill for adults with major depressive disorder. After prescription growth slowed in July and August, volume rebounded to reach a monthly high of about 1,650 prescriptions in September.
- EXXUA net revenue: $4.9 million, up 24.5% from last quarter and 33.0% of total sales by our math
- Total prescriptions: 4,400, up 32.5% from last quarter (1,077 net new prescriptions by our math)
- Revenue per prescription: $1,114 by our math, compared with $1,184 in the fourth quarter
The September rebound matters because it shows the newly rebuilt sales force is winning prescriptions faster. However, the drugmaker notes that EXXUA revenue reflects "product sales into the distribution channel and gross-to-net estimates". By our math, Aytu booked $1,114 per prescription, well above the $740 per prescription management previously linked to underlying patient demand, so wholesaler stocking may still be lifting sales.
What to watch: EXXUA unit shipments in the first-quarter filing. A shipment figure close to 4,400 units would show that pharmacy demand is catching up with wholesale deliveries.
Pediatric Sales Tripled on Fewer Returns
Aytu's pediatric portfolio sells prescription multivitamins, allergy treatments and cough medicines for children. The drugmaker had reduced marketing for these products over the past year to focus on central nervous system treatments, and supplier delays plus product returns hurt results a year ago.
This quarter, pediatric revenue jumped to $2.2 million from $0.7 million a year ago, a 208.4% increase by our math, and rose 21.8% from the fourth quarter. Aytu said the rebound came from "improved payer mix and lower returns, particularly within the multivitamin product line". The extra $1.5 million in revenue helped offset the steep drop in the older attention-deficit drugs.
What to watch: pediatric net revenue in the second quarter. Staying above $2.0 million would show that the better insurance reimbursement is lasting rather than a one-time drop in returns.
Positives this quarter didn't test
Because of the pending buyout, Aytu cancelled its conference call and left two standing operational drivers without an update while continuing to pay down debt.
- Debt reduction: total debt fell 3.1% from last quarter to $16.5 million by our math after $0.5 million in debt repayments; the quarterly filing will detail the remaining credit facility terms.
- EXXUA insurance approvals: prior-authorization approval rates (~70% last quarter without payer rebates) were not updated; the quarterly filing's gross-to-net footnotes will give the next read.
- Prescriber breadth and rep productivity: unique prescribing doctors (~1,200 last quarter) and weekly prescriptions per sales representative were omitted without a call.
π» Bear Case
ADHD Sales Dropped 41% Under Generic Pressure
Aytu sells branded drugs for attention-deficit hyperactivity disorder (ADHD), led by Adzenys XR-ODT and Cotempla XR-ODT. Management has long framed this legacy portfolio as a source of steady cash that would fund the EXXUA rollout. Instead, ADHD revenue fell 41.2% from a year ago and 25.3% from last quarter to $7.7 million, the lowest quarterly level in the past two years.
The Denver-based company blamed "reduced promotional emphasis as commercial resources shifted toward EXXUA and generic competition" against Adzenys. The $5.4 million year-over-year drop in ADHD sales completely wiped out the $4.9 million gained from launching EXXUA. Without the rebound in pediatric multivitamins, total company revenue would have shrunk.
What to watch: ADHD portfolio disclosures in the quarterly filing. Any mention of a generic launch against Cotempla, which became eligible for generic entry in July 2026, would mean the legacy decline will deepen.
Launch and Merger Costs Widened Operating Losses
Last quarter, Aytu returned to a positive $0.5 million in Adjusted EBITDA, which is operating profit before interest, taxes, depreciation, stock pay and warrant gains. Management also said it planned to reach positive Adjusted EBITDA across the second half of fiscal 2027. In the first quarter, however, Adjusted EBITDA fell back to a loss of $2.6 million, four times the $0.6 million loss a year ago.
- Gross margin: 63.6%, down 2.6 percentage points from a year ago as cost of goods sold rose to 36.4% of revenue
- Selling and marketing (advertising and sales reps): 44.6% of revenue, up 6.3 percentage points from a year ago by our math
- General and administrative (overhead and legal): 40.3% of revenue, up 4.9 percentage points from a year ago by our math
- Operating loss: $3.9 million (-26.5% of revenue), compared with $1.5 million (-10.8% of revenue) a year ago
Gross margin slipped because Aytu paid "increased royalty expense, primarily related to EXXUA" and took $0.4 million in inventory write-downs. Meanwhile, overhead climbed due to EXXUA sales travel, merger legal bills, and a "cancellation charge incurred with a contract manufacturing organization". Even so, operating cash burn was just $0.3 million because the drugmaker collected $2.4 million from customer receivables.
What to watch: the exact dollar size of the merger legal fees and the manufacturing cancellation charge in the quarterly filing. Large one-time charges would mean underlying launch costs are closer to breakeven than the $3.9 million operating loss suggests.
Risks this quarter didn't answer
Three standing risks from prior quarters received no new figures in the earnings release.
- EXXUA channel inventory: unit shipments to wholesalers were not disclosed this quarter, leaving open how much of the $4.9 million in sales stayed on wholesaler shelves.
- Short EXXUA patent runway: protection runs only through September 2030 alongside a 28%-plus royalty obligation; any patent extension update waits for the quarterly filing.
- Wholesaler concentration: five distributors account for the bulk of gross revenue; updated concentration percentages will appear in the quarterly filing footnotes.
π Other Themes
Rosemont Agrees to Buy Aytu for $56 Million
"Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash," Disbrow said. The deal values the pharmaceutical group at about $56 million on a fully diluted basis. Disbrow cited a "strong strategic fit between our portfolio and Rosemontβs experience developing and commercializing specialty medicines", and expects the buyout to close by the end of calendar 2026.
π² Other KPIs
Cash dipped $0.8 million from $26.3 million in June. Operating activities used only $0.3 million of cash despite the $3.9 million net loss, while debt repayments used another $0.5 million. Cash has fallen gently over the past four quarters from $32.6 million a year ago.
Money owed by wholesalers dropped 10.7% from $22.8 million in June by our math, outpacing the 7.8% sequential dip in revenue. Collecting those bills kept operating cash burn down to $0.3 million even as launch spending rose.
Stock on hand fell 12.2% from $6.9 million in June by our math and is down from $10.1 million a year ago. The drop reflects $0.4 million in inventory write-downs this quarter alongside shipments of EXXUA into the wholesale channel.
Weighted-average diluted shares edged down 0.8% from 19.5 million a year ago by our math and held steady against the fourth quarter. The count includes prefunded warrants issued during the June 2025 fundraising.
β Key Questions
How many EXXUA units were shipped to wholesalers?
In the prior two quarters, unit shipments exceeded filled prescriptions, building wholesale stock. Without this quarter's shipment count, investors cannot tell how much of the $4.9 million in EXXUA revenue came from patient demand versus distributor stocking.
How large were the merger and manufacturing cancellation charges?
General and administrative expenses jumped by $1.1 million from a year ago, driven by merger legal bills and a contract manufacturer cancellation fee. Knowing the exact dollar amounts will show the true ongoing cost of running the EXXUA launch.
Did a generic competitor launch against Cotempla XR-ODT?
ADHD revenue dropped 25.3% in a single quarter to $7.7 million. While the release cites Adzenys generic competition and less marketing, Cotempla became eligible for a generic rival in July 2026, and the filing should clarify if that rival entered.
What are the break fees in the Rosemont merger?
Rosemont plans to buy Aytu through a cash tender offer by the end of calendar 2026. The upcoming tender documents will show the minimum share tender conditions, regulatory hurdles, and what happens if the deal falls through.
